Management of Bilateral Breast Malignancy

Initial Diagnostic Workup

Each breast lesion requires independent pathologic confirmation via core needle biopsy before any surgical intervention, according to the American College of Surgeons 1
Obtain complete pathologic assessment for both tumors including: histological type and grade, ER/PR status by immunohistochemistry, HER2 status, and Ki67 proliferation markers, as recommended by the American Society of Clinical Oncology 3
Perform bilateral diagnostic mammography to identify extent of disease and rule out additional lesions, as suggested by the American College of Radiology 1
Stage each breast cancer independently using the TNM system, following the guidelines of the American Joint Committee on Cancer 3
Complete staging workup includes: physical examination focusing on family history and genetic risk factors, CBC and routine chemistry, chest imaging (X-ray or CT), abdominal ultrasound or CT, and bone scan for higher-risk disease, as recommended by the National Comprehensive Cancer Network 1, 3
Genetic counseling is mandatory given the bilateral presentation, particularly to assess for BRCA1/2 mutations, according to the American Society of Clinical Oncology 1, 2

Bilateral total mastectomy with removal of all breast tissue is the recommended surgical approach for most patients with bilateral malignant breast masses, as stated by the American Society of Breast Surgeons 1
Perform sentinel lymph node biopsy for each breast separately when invasive cancer is present, following the guidelines of the American Society of Clinical Oncology 1, 3
Avoid complete axillary lymph node dissection unless there is proven metastatic disease, as recommended by the American College of Surgeons 1
Immediate breast reconstruction is appropriate and should be discussed with all patients, according to the American Society of Plastic Surgeons 1

Breast conservation therapy is feasible for bilateral disease only when ALL of the following criteria are met: clear surgical margins achievable in both breasts, tumor size relative to breast volume allows adequate resection in both breasts, absence of multicentric disease, no prior chest wall irradiation, and patient can tolerate mandatory bilateral whole breast radiation therapy, as stated by the American Society of Radiation Oncology 2
Patients choosing bilateral breast conservation must understand that radiation therapy to both breasts is absolutely mandatory—omitting radiation results in unacceptably high local recurrence rates, according to the American Society of Clinical Oncology 2

Treatment decisions must be based on the biological characteristics of the more advanced lesion, considering tumor stage, hormone receptor status, HER2 status, and axillary lymph node involvement, as recommended by the National Comprehensive Cancer Network 1, 3
For hormone receptor-positive tumors: endocrine therapy is mandatory, according to the American Society of Clinical Oncology 3
For HER2-positive tumors: anti-HER2 therapy plus chemotherapy, as stated by the American Society of Clinical Oncology 3
For triple-negative tumors: chemotherapy is the mainstay, with consideration of immunotherapy if PD-L1 positive, according to the American Society of Clinical Oncology 3
When tumors have discordant biology between breasts, treat according to the more aggressive phenotype, as recommended by the National Comprehensive Cancer Network 1

For bilateral breast conservation: Postoperative whole breast radiation therapy is mandatory for both breasts, reducing local recurrence risk by two-thirds and providing survival benefit, according to the American Society of Radiation Oncology 2
Boost irradiation to tumor beds indicated for: age <50 years, grade 3 tumors, vascular invasion, or focally positive margins, as recommended by the American Society of Radiation Oncology 2
For bilateral mastectomy: Post-mastectomy radiotherapy recommended for patients with four or more positive axillary nodes or T3 tumors with positive nodes, according to the American Society of Clinical Oncology 3

BRCA1/2 carriers can safely undergo bilateral breast conservation therapy, but face a 25-31% 10-year risk of developing new breast cancer and should be counseled about bilateral mastectomy as a definitive risk-reducing option, as stated by the American Society of Clinical Oncology 2
With bilateral mastectomy, risk for subsequent breast cancer incidence and mortality is reduced by 90-95%, according to the European Society for Medical Oncology 4
If BRCA carriers choose breast conservation, radiation therapy is essential and cannot be omitted, as recommended by the American Society of Radiation Oncology 2
Consider risk-reducing salpingo-oophorectomy per genetic/familial high-risk assessment guidelines, according to the American College of Obstetricians and Gynecologists 1

Annual clinical examinations of the chest/reconstructed breast after bilateral mastectomy, as recommended by the American Society of Clinical Oncology 1
Mammograms are NOT recommended after bilateral mastectomy, according to the American College of Radiology 1
For breast conservation patients: regular mammographic surveillance of both breasts, as stated by the American College of Radiology 3
Focus on surveillance for recurrence and routine health maintenance, according to the American Society of Clinical Oncology 1

Never perform unilateral mastectomy when bilateral malignancy is confirmed—the risk is equal in both breasts, as stated by the American Society of Breast Surgeons 1
Do not delay tissue biopsy, as this delays treatment of malignancy, according to the American College of Surgeons 1
Do not omit genetic counseling in bilateral breast cancer, as this presentation strongly suggests possible hereditary cancer syndrome, as recommended by the American Society of Clinical Oncology 1, 2
Do not automatically recommend bilateral mastectomy simply because disease is bilateral—this represents overtreatment in appropriately selected breast conservation candidates, according to the American Society of Breast Surgeons 2
Never counsel patients that mastectomy provides superior survival to breast conservation in early-stage disease—outcomes may be equal or better with breast conservation when properly selected, as stated by the European Society for Medical Oncology 4, 2